Cambridge Investment Research Advisors, Inc.
Position in GANX — Gain Therapeutics, Inc.
CIK 1419186
FAIRFIELD, IA
Position in GANX
as of Jun 30, 2026
· filed Jul 30, 2026
Position Value
$1,154,349
+$51,178 QoQ
Shares Held
568,645
0.0% QoQ
Ownership
1.30%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#5
of 49 holders
Holding Since
Dec 2024
7 quarters on record
Common Shares in GANX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Cambridge Investment Research Advisors, Inc. holds $60,632,692 across 72 Biotechnology names. GANX ranks #14 (1.9% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
21,946 | $10,901,236 | |
| 2 | EXEL |
Exelixis, Inc.
|
82,212 | $4,473,154 | |
| 3 | NKTR |
Nektar Therapeutics
|
56,186 | $3,922,344 | |
| 4 | CORT |
Corcept Therapeutics Inc
|
35,157 | $3,056,901 | |
| 5 | RVMD |
Revolution Medicines, Inc.
|
15,839 | $2,966,327 | |
| 6 | REGN |
Regeneron Pharmaceuticals, Inc.
|
4,591 | $2,862,672 | |
| 7 | CRSP |
CRISPR Therapeutics AG
|
46,210 | $2,520,293 | |
| 8 | BBIO |
BridgeBio Pharma, Inc.
|
30,727 | $2,288,546 |
All Filings in GANX
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1,154,349 | 568,645 | Shares | Sole | 2026-07-30 | |
| 2026-03-31 | $1,103,171 | 568,645 | Shares | Sole | 2026-04-30 | |
| 2025-12-31 | $1,831,036 | 568,645 | Shares | Sole | 2026-02-05 | |
| 2025-09-30 | $564,001 | 318,645 | Shares | Sole | 2025-11-12 | |
| 2025-06-30 | $323,100 | 179,500 | Shares | Sole | 2025-07-31 | |
| 2025-03-31 | $113,645 | 59,500 | Shares | Sole | 2025-04-22 | |
| 2024-12-31 | $117,720 | 54,500 | Shares | Sole | 2025-02-14 | |
| No filing history on record for this holder in this stock. | ||||||